Characteristics of asymptomatic secondary immune responses to measles virus in late convalescent donors

Clinical and Experimental Immunology

Volumn 109, Issue 3, 1997, Pages 416-420

  Huiss, S ^a,c   Damien, B ^a   Schneider, F ^b   Muller, C P ^a,b,c  

^a Department of Immunology ^*  (Luxembourg)

^b LABORATOIRE NATIONAL DE SANTÉ   (Luxembourg)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Immunoglobulin subclasses; Measles; Secondary immune response

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; IMMUNOGLOBULIN SUBCLASS; NEUTRALIZING ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VIRUS; PRIORITY JOURNAL; VACCINATION; VIREMIA; VIRUS TRANSMISSION;

EID: 0030868067     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.00137.x     Document Type: Article

References (23)

1. Panum PL. Observations made during the epidemic of measles on the Faroe Islands in the year 1849. New York: American Publishing Association, 1940.
2. Mitchell CD, Balfour HHJ. Measles control: so near and yet so far. Prog Med Virol 1985; 31:1-42.
3. Frank JA Jr, Orenstein WA, Bart KJ et al. Major impediments to measles elimination. The modern epidemiology of an ancient disease. Am J Dis Child 1985; 139:881-8.
4. Gustafson TL, Lievens AW, Brunell PA, Moellenberg RG, Buttery CM, Sehulster LM. Measles outbreak in a fully immunized secondary-school population. N Engl J Med 1987; 316:771-4.
5. Pedersen IR, Mordhorst CH, Glikmann G, von Magnus H. Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland. Vaccine 1989; 7:345-8.
6. Christenson B, Böttiger M. Measles antibody: comparison of long-term vaccination titres and naturally acquired immunity to and booster effect on the measles virus. Vaccine 1994; 12:129-33.
7. Muller CP, Huiss S, Schneider F. Secondary immune responses in parents of children with recent measles. Lancet 1996; 348:1379-80.
8. Norrby E. Hemagglutination by measles virus. 4. A simple procedure for production of high potency antigen for hemagglutination inhibition (HI) tests. Proc Soc Exp Biol Med 1962; 11:814-8.
9. Center for Disease Control. Case definitions for public health surveillance. Morbid Mortal Weekly Rep 1990; 39:13.
10. Norrby E, Gollmar Y. Appearance and persistence of antibodies against different virus components after regular measles infections. Infect Immun 1972; 6:240-7.
11. Aaby P, Bukh J, Leerhoy J, Lisse IM, Mordhorst CH, Pedersen IR. Vaccinated children get milder measles infection: a community study from Guinea-Bissau. J Infect Dis 1986; 154:858-63.
12. Ozanne G, d'Halewyn MA. Secondary immune response in a vaccinated population during a large measles epidemic. J Clin Microbiol 1992; 30:1778-82.
13. Mathiesen T, Hammarstrom L, Fridell E et al. Aberrant IgG subclass distribution to measles in healthy seropositive individuals, in patients with SSPE and in immunoglobulin-deficient patients. Clin Exp Immunol 1990; 80:202-5.
14. Norrby E, Orvell C, Vandvik B, Cherry JD. Antibodies against measles virus polypeptides in different disease conditions. Infect Immun 1981; 34:718-24.
15. Murray DL, Lynch MA. Determination of immune status to measles, rubella, and varicella-zoster viruses among medical students: assessment of historical information. Am J Public Health 1988; 78:836-8.
16. Sekla L, Stackiw W, Eibisch G, Johnson I. An evaluation of measles serodiagnosis during an outbreak in a vaccinated community. Clin Invest Med 1988; 11:304-9.
17. Poland GA, Hayney MS, Schaid DJ, Jacobson RM, Lipsky JJ. Class II HLA-DR homozygosity is associated with non-response to measles vaccine in U. S. children. FASEB J 1995; 9:A240-1397.
18. Hayney MS, Poland GA, Dimanlig P, Schaid DJ, Jacobson RM, Lipsky JJ. Polymorphism of the TAP2 gene may influence antibody response to live measles vaccine virus. Vaccine 1997; 15:3-6.
19. Markowitz LE, Albrecht P, Orenstein WA, Lett SM, Pugliese TJ, Farrell D. Persistence of measles antibody after revaccination. J Infect Dis 1992; 166:205-8.
20. Edmonson MB, Addiss DG, McPherson JT, Berg JL, Circo SR, Davis JP. Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. JAMA 1990; 9:2467-71.
21. Weibel RE, Buynak EB, McLean AA, Roehm RR, Hilleman MR. Persistence of antibody in human subjects for 7-10 years following administration of combined live attenuated measles, mumps, rubella virus vaccines. Proc Soc Exp Biol Med 1980; 165:260-3.
22. Krugman S. Further-attenuated measles vaccine: characteristics and use. Rev Infect Dis 1983; 5:477-81.
23. Pedersen IR, Mordhorst CH, Ewald T, von Magnus H. Long-term antibody response after measles vaccination in an isolated arctic society in Greenland. Vaccine 1986; 4:173-8.